Two patents currently held, every record listed here
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2028. from the record
Of the 6 now held by other companies, 4 name AbbVie Inc. as their current owner, and 2 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Oct 2028
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2012 to 2032.
US 10,072,256
Process for Separating and Determining the Viral Load in a Pancreatin Sample
Oct 11, 2028
US 9,080,193
Preparation of (3aS,7aR)-HEXAHYDROISOBENZOFURAN-1(3H)-ONE by Catalyzed Biological Resolution of Dimethyl CYCLOHEXANE-1,2-Dicarboxylate
May 24, 2031
20162020202420282032
Every computed term in this portfolio is shown above.Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Oct 2028 · High confidence
Also notable
Ends Feb 2030 · High confidence
Process for Separating and Determining the Viral Load in a Pancreatin Sample
US 10,072,256
Cited by 63 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2028.
Delayed Release Pancreatin Compositions
US 9,198,871
The most cited patent in this portfolio, cited by 66 later US patents, top 10% of utility patents granted in 2015 in our data. Protection runs to 2030.
Formerly held, still cited
Notable
Ends Mar 2029 · High confidence
The most cited patent in this portfolio, cited by 73 later US patents, top 1% of utility patents granted in 2022 in our data. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
now held by AbbVie Pharmaceuticals GmbH
Also notable
Ends Nov 2028 · High confidence
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2028.
now held by Novozymes A/S
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 1, 2027The maintenance fee for Delayed Release Pancreatin Compositions (US 9,198,871) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Delayed Release Pancreatin Compositions | 1 in force | to Feb 2030 |
| Process for Separating and Determining the Viral Load in a Pancreatin Sample | 1 in force | to Oct 2028 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,072,256 | Process for Separating and Determining the Viral Load in a Pancreatin Sample In force · High confidence | In force | High confidence | |
| US 9,198,871 | Delayed Release Pancreatin Compositions In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 6 patents in force now held by others · 26 patents ended · 19 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed